Back to News
Market Impact: 0.3
Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates
Source: zacks.com
Corporate EarningsHealthcare & BiotechAnalyst Estimates
Aytu BioPharma reported a quarterly loss of $0.05 per share, substantially better than the Zacks consensus forecast for a $0.22 loss. The result also improved from a $0.26 per-share loss in the prior-year quarter, indicating a $0.21 year-over-year reduction in losses.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.48
Ticker Sentiment
AYTU0.72
More News
- Heidi CEO on AI in Healthcare, $900M valuation
- Lennar shares pop as Berkshire builds almost a 10% stake in beleaguered homebuilder
- Guggenheim Names Top Stock Pick in Biotech Sector
- S&P 500 Profits Are on Track for a Third Straight Quarter of 25%+ Growth. The Index Hasn't Kept Up.
- Cisco stock sinks 5% after Piper Sandler cuts price target on growth concerns
- Activist Jana Partners calls for Six Flags sale- WSJ
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Research Workflows, Report Format Selection, and Interactive Synthesis
- Can ChatGPT Analyze a 10-K? A Verification Workflow